Last updated: August 19, 2026
PlushCare and Mochi Health take different approaches to GLP-1 weight-loss care. PlushCare’s GLP-1 program is built around full-service virtual primary care, insurance handling, and brand-name medications, while Mochi Health emphasizes predictable self-pay pricing, live video visits, compounded medication options, bariatric specialists, and dietitian access.
Both providers are classified as Top Tier under the GLP-1 Reviews provider scoring methodology, but their strengths apply to different patient situations. The more useful question is not which provider is universally better; it is whether you need primary-care integration and insurance support or a flat-rate specialist program for self-pay treatment.
PlushCare vs. Mochi Health at a glance
| Comparison factor | PlushCare | Mochi Health |
|---|---|---|
| Care model | Full-service virtual primary care with GLP-1 prescribing | Dedicated weight-management telehealth with live video provider visits |
| Primary medication focus | Brand-name GLP-1s, including Wegovy, Zepbound, Ozempic, and other FDA-approved options listed on its review page | Compounded semaglutide and tirzepatide, with brand-name options also listed |
| Published pricing structure | $19.99 monthly membership plus $129 per visit; NovoCare Wegovy from $199/month introductory pricing verified July 2026 | $39 first-month promotion; $178/month all-in semaglutide; $278/month all-in tirzepatide |
| Medication included in program price? | No. Medication and clinical visit costs are separate components | All-in medication pricing is published for the specified semaglutide and tirzepatide options |
| Insurance | Accepted; insurance-first model for eligible patients | Flat-rate self-pay structure is central to the comparison; verify whether insurance reimbursement applies to your plan |
| Prescriber model | Primary-care telehealth clinicians | Live video providers, including bariatric specialists |
| Nutrition support | Primary-care approach; dietitian access is listed on the review page | Dietitian access included |
| Laboratory testing | Lab testing handled through primary care; not presented as an included standalone program benefit | Lab testing is not included; patients arrange bloodwork separately |
| Compounding focus | No compounding focus | Compounded options |
| Geographic availability | Nationwide telehealth availability listed on the review page, subject to state and clinical requirements | Available in all 50 states |
| Compliance and reputation signals | 3.4 Trustpilot rating noted on the review page | 4.4 Trustpilot rating across 15,600+ reviews noted on the review page |
| GLP-1 Reviews rating | 4.6/5.0 , Top Tier | 4.8/5.0 , Top Tier |
| Key tradeoff | More integrated medical access, but visit-based pricing can make total cost less predictable | More predictable self-pay pricing, but compounded medication options are not FDA-approved formulations |
The central difference: primary care versus dedicated weight management
The most important distinction is structural.
PlushCare treats GLP-1 care as part of a broader virtual primary-care relationship. A patient may use the platform for weight management while also discussing other health concerns with a primary-care clinician. The GLP-1 pathway includes a live physician visit, and the platform’s medication menu focuses on brand-name products such as semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro).
Mochi Health is more narrowly organized around weight management and related health support. Its care model includes live video provider visits, bariatric specialists, and dietitian access. The program is designed for patients who want a dedicated obesity-care pathway rather than adding a GLP-1 conversation to a broader primary-care appointment.
That difference affects the patient journey:
- PlushCare may make more sense when insurance, primary-care continuity, and brand-name medication access are the priorities.
- Mochi may make more sense when predictable self-pay pricing and specialist weight-management support matter more.
- Neither model automatically fits every patient. Eligibility, medication selection, dosing, and follow-up remain clinical decisions.
Pricing comparison: what each monthly price does and does not include
Pricing is one of the clearest differences between PlushCare and Mochi Health, but the numbers should not be compared without looking at what each figure represents.
PlushCare pricing
The PlushCare review page lists a $19.99 monthly membership plus $129 per visit. Those are care-access costs, not a bundled medication price.
For medication, the verified July 2026 pricing information lists NovoCare Wegovy from $199 per month at introductory pricing. The medication is handled separately from PlushCare’s membership and visit fees. That means a patient considering the NovoCare Wegovy option should treat the $199 figure as a medication price, not as the total cost of PlushCare care.
A simplified way to understand the structure is:
- Monthly membership: $19.99
- Clinical visit: $129 per visit
- Wegovy through the verified NovoCare introductory option: from $199 per month
- Insurance contribution: varies according to the patient’s plan and eligibility
- Total treatment cost: depends on the number of visits, medication route, and coverage
The key advantage is flexibility. Patients with insurance may have a different out-of-pocket medication cost than self-pay patients. However, that same flexibility makes the total monthly amount less predictable before the patient confirms coverage and learns how often follow-up visits will be required.
PlushCare’s pricing should therefore be evaluated as a component-based model. The membership, visit, and medication are separate pieces. A patient should ask:
- Is the $19.99 membership required for ongoing care?
- How often will follow-up visits be needed?
- Will the plan submit or support insurance authorization?
- Which pharmacy will dispense the prescribed medication?
- Does the $199 NovoCare figure apply to the selected dose and current eligibility requirements?
The answer to these questions may matter more than the headline medication price.
Mochi Health pricing
Mochi Health publishes a more predictable self-pay structure for the options supplied for this comparison:
- $39 first-month promotional price
- $178 per month all-in for semaglutide
- $278 per month all-in for tirzepatide
The all-in figures are intended to make the relationship between the program and medication cost easier to understand. Unlike a model that separates membership from medication, the supplied Mochi figures present a combined monthly amount for the specified treatment options.
The $39 figure is a first-month promotion, so it should not be treated as the standard long-term price. Patients should confirm the length and terms of the promotion, including whether it applies to the membership, medication, or both. After the promotional period, the comparison should use the published all-in price that corresponds to the medication selected.
Mochi’s pricing structure is easier to budget for when a patient is paying out of pocket:
- Promotional first month: $39
- Ongoing semaglutide price: $178 per month all-in
- Ongoing tirzepatide price: $278 per month all-in
That predictability is useful, but it does not answer every cost question. Patients should still verify shipping, refill timing, lab expenses, cancellation rules, and whether a change in medication changes the monthly price. The all-in figure should be read as the published program price for the named medication, not as a guarantee that every possible healthcare expense is covered.
What the pricing models mean for self-pay patients
For a self-pay consumer, Mochi’s pricing is easier to forecast because the comparison provides an all-in monthly amount for semaglutide and tirzepatide.
PlushCare requires more individual calculation. The $19.99 membership and $129 visit price are clear, but the medication cost depends on the selected brand, pharmacy route, insurance status, and current manufacturer pricing. The verified NovoCare Wegovy price from $199 per month may be attractive for eligible patients, but it is not the complete PlushCare treatment cost.
This creates two different forms of price transparency:
- PlushCare: transparent components, with the final total depending on insurance and utilization.
- Mochi Health: transparent all-in figures for specified self-pay medication options, with promotional terms requiring confirmation.
A buyer comparing the two should not compare $199 with $178 as if they were equivalent. The first is a medication price from a manufacturer-affiliated cash-pay route, while the second is an all-in Mochi price for semaglutide. The care fees and medication arrangements are structured differently.
Medication access: brand-name focus versus compounded options
PlushCare’s brand-name medication model
PlushCare’s strongest differentiator is its focus on brand-name, FDA-approved GLP-1 medications. The review page lists options including:
- Semaglutide brands such as Wegovy and Ozempic
- Tirzepatide brands such as Zepbound and Mounjaro
- Other brand-name products listed on the provider review page, including Saxenda, Victoza, and Rybelsus
The exact medication a clinician prescribes depends on the patient’s medical history, eligibility, treatment goals, insurance coverage, and medication availability. A patient can express a preference, but a provider determines whether that medication is clinically appropriate.
PlushCare has no compounding focus in the verified data for this comparison. That may appeal to patients who specifically want a brand-name product dispensed through a conventional pharmacy or manufacturer cash-pay channel.
The tradeoff is that brand-name medication pricing and coverage can be more complicated. Insurance may require prior authorization, impose formulary restrictions, or exclude weight-loss medications. A patient may also face different costs depending on whether the prescription is being used for diabetes care or chronic weight management.
Mochi Health’s compounded and brand-name options
Mochi Health’s comparison profile centers on compounded semaglutide and compounded tirzepatide at published all-in prices. It also lists brand-name Wegovy and Zepbound options.
The main distinction is that compounded products are not FDA-approved formulations in the same way as the branded products Wegovy and Zepbound.
Patients considering Mochi should ask which medication formulation is being offered, which pharmacy is dispensing it, how the medication is labeled and shipped, and what happens if availability or compounding rules change. These questions are especially important because compounded medication access can depend on regulatory and supply conditions.
The practical medication choice is therefore:
- Choose the PlushCare pathway when brand-name access is central to your decision.
- Consider Mochi when you are evaluating compounded options and value specialist support and a published all-in price.
- Ask a licensed clinician whether the formulation and medication are appropriate for your health history.
Clinical model: PCP-integrated care versus specialist support
PlushCare’s primary-care approach
PlushCare’s clinical model is designed to place GLP-1 treatment inside a broader primary-care relationship. That can be helpful for patients who want to discuss weight, blood pressure, metabolic health, medication interactions, or other conditions in one clinical setting.
The supplied data also identifies lab testing through primary care. This means patients who need laboratory monitoring may coordinate testing through their primary-care pathway, although lab testing is not described as an included standalone program benefit. Patients should confirm which tests are recommended, where testing takes place, and whether their insurance covers the service.
The advantages of this model include:
- Broader health context around the GLP-1 prescription
- Insurance acceptance
- Access to brand-name medications
- Primary-care coordination
- A live clinical visit rather than prescription access based only on a short form
The possible limitation is that patients seeking highly specialized obesity medicine may prefer a program built specifically around weight management rather than a general primary-care platform.
Mochi Health’s specialist and dietitian model
Mochi Health includes access to bariatric specialists and dietitians. That gives the program a more focused weight-management structure.
The dietitian component may be particularly relevant to patients who want help building eating patterns and maintaining changes alongside medication. Bariatric specialists may offer a more targeted perspective on obesity treatment than a general primary-care appointment, although the quality and availability of individual care can vary by clinician and patient circumstances.
Mochi uses a live video provider visit model. That is important because the patient’s medical assessment occurs through a real-time clinical encounter rather than being based solely on automated eligibility questions.
Mochi’s strengths in this category include:
- Dedicated weight-management focus
- Live video provider access
- Bariatric specialist availability
- Dietitian access included
- A self-pay structure that combines care and medication pricing for the specified options
The main limitation is that laboratory testing is not included, so patients may need to arrange bloodwork separately.
Insurance handling and access
Insurance is a major dividing line.
PlushCare accepts insurance and is positioned as an insurance-first option. For patients whose plan covers a brand-name GLP-1, PlushCare may provide a pathway that includes insurance billing, clinical evaluation, and pharmacy coordination. Coverage is never automatic, however. The patient’s insurer may require prior authorization or may exclude medications prescribed primarily for weight management.
Insurance acceptance does not mean that every medication is covered. Before enrolling, confirm:
- Whether your plan includes Wegovy, Zepbound, Ozempic, or another prescribed medication
- Whether the medication requires prior authorization
- Whether the medication is covered for your diagnosis
- Whether PlushCare clinicians can submit the required documentation
- What your visit copay and deductible obligations are
Mochi’s published comparison pricing is designed around self-pay access. The $178 all-in semaglutide price and $278 all-in tirzepatide price do not require a patient to first establish insurance coverage in order to understand the advertised monthly cost. That can simplify budgeting for people whose plans do not cover weight-loss medication.
Because insurance reimbursement rules vary, patients should confirm directly with Mochi and their insurer whether any portion of the program or medication can be reimbursed. Do not assume that an all-in self-pay price will process like a standard insurance prescription.
Availability and onboarding
Mochi Health is listed as available in all 50 states. Patients still need to meet state-specific and clinical requirements, but broad geographic availability is a notable access advantage for people who move frequently or live outside major metropolitan areas.
PlushCare is also presented as a nationwide telehealth provider on its review page. Its access model is more closely connected to the availability of licensed clinicians in the patient’s state and the insurance or pharmacy route being used.
Both providers use live video care, but the surrounding experience differs:
- PlushCare’s onboarding leads into a full-service primary-care appointment.
- Mochi’s onboarding leads into a dedicated weight-management provider visit.
- PlushCare’s medication access is more closely tied to brand-name prescriptions and insurance or manufacturer cash-pay routes.
- Mochi’s specified pricing is built around self-pay compounded medication options.
Patients should confirm current state availability, appointment timing, medication availability, and dispensing arrangements before paying.
Reputation, transparency, and consumer protections
The GLP-1 Reviews scores should be interpreted through the published methodology rather than treated as a universal ranking.
PlushCare is rated 4.6/5.0 and Top Tier. Its review identifies strong access and authenticity signals, while also noting a 3.4 Trustpilot rating and complaints involving billing and scheduling. PlushCare’s established primary-care model and brand-name medication focus are important positives for patients who prioritize conventional medication sourcing and broader care.
Mochi Health is rated 4.8/5.0 and Top Tier. Its review highlights dietitian access and bariatric specialist availability.
The relevant tradeoffs are different:
- PlushCare’s transparency is strongest around its full-service model, brand-name medication menu, insurance acceptance, and separate membership and visit pricing.
- Mochi’s transparency is strongest around its all-in pricing for the specified options.
- PlushCare’s primary concern is the possibility of variable total costs and reported billing or scheduling friction.
- Mochi’s primary concern is the regulatory distinction between compounded and FDA-approved branded formulations.
Read the provider-specific review pages before enrolling, and review cancellation, refill, refund, and medication-discontinuation terms directly with the provider.
Best for different patient scenarios
Best for patients who want insurance-first brand-name access: PlushCare
PlushCare is the more natural fit for patients who want to pursue brand-name medications through insurance or an established manufacturer cash-pay route. The platform’s full-service primary-care structure may also be useful for people managing multiple health concerns.
Best for patients who want predictable self-pay pricing: Mochi Health
Mochi is the clearer fit for patients who want a published all-in monthly price for semaglutide or tirzepatide. The $178 semaglutide and $278 tirzepatide figures provide a more direct budgeting framework than a membership-plus-visit model with medication billed separately.
Best for patients who prioritize bariatric specialists and dietitian access: Mochi Health
Mochi includes access to bariatric specialists and dietitians. That combination may appeal to patients looking for dedicated weight-management support beyond the prescription itself.
Best for patients who specifically want brand-name GLP-1s: PlushCare
PlushCare’s verified profile emphasizes brand-name GLP-1 medications and does not focus on compounding. Patients who do not want compounded formulations may prefer this route, subject to clinical eligibility, coverage, and availability.
Best for patients who want broader primary-care integration: PlushCare
PlushCare is designed as a full-service primary-care telehealth platform. It may be a better scenario fit for someone who wants GLP-1 treatment discussed alongside other primary-care needs rather than through a weight-management-only service.
Questions patients ask about PlushCare and Mochi Health
Is PlushCare or Mochi Health cheaper for GLP-1 weight loss in 2026?
Mochi Health has the more predictable published self-pay price: $178 per month all-in for semaglutide and $278 per month all-in for tirzepatide, after a $39 first-month promotion. PlushCare’s costs are separated into a $19.99 monthly membership, $129 visits, and medication pricing such as NovoCare Wegovy from $199 per month at verified July 2026 introductory pricing. Insurance can materially change PlushCare’s final out-of-pocket cost.
Does PlushCare accept insurance for GLP-1 medications?
Yes, PlushCare accepts insurance and uses an insurance-first primary-care model. However, acceptance of insurance does not guarantee coverage for a specific GLP-1. Your plan may require prior authorization, restrict the medication to certain diagnoses, or exclude weight-loss treatment. Confirm formulary status, authorization requirements, visit costs, and pharmacy options before assuming insurance will reduce the medication price.
Does Mochi Health offer compounded semaglutide and tirzepatide?
Yes, Mochi Health’s verified comparison data lists compounded semaglutide and compounded tirzepatide, priced at $178 and $278 per month all-in, respectively. Compounded products are not FDA-approved formulations in the same way as branded Wegovy or Zepbound, so patients should discuss formulation, sourcing, labeling, and clinical appropriateness with a licensed provider.
Which provider offers more specialized weight-loss support?
Mochi Health offers bariatric specialists and dietitian access as part of its dedicated weight-management model. PlushCare provides a full-service primary-care model and also lists dietitian access, but its defining structure is broader primary-care integration rather than a specialist-only weight-management pathway. The better fit depends on whether you prioritize obesity-medicine specialization or coordination with general primary care.
Are PlushCare and Mochi Health available nationwide?
Both are presented as nationwide telehealth options, while Mochi Health is specifically listed as available in all 50 states. Availability still depends on state licensing, clinical eligibility, appointment capacity, and medication fulfillment. Confirm service availability in your state and the exact dispensing route before enrolling or paying for a program.
Conclusion: two credible models for different priorities
PlushCare and Mochi Health represent two distinct approaches to GLP-1 care in 2026.
PlushCare is built for patients who want full-service virtual primary care, insurance handling, and access to brand-name GLP-1 medications. Its $19.99 membership and $129 visit structure is separate from medication costs, while verified July 2026 NovoCare Wegovy introductory pricing starts at $199 per month. The model may be especially relevant for insured patients and people who want broader medical care around their weight-management treatment.
Mochi Health is built for patients who want a dedicated weight-management program with live video provider visits, bariatric specialists, dietitian access, and a more predictable self-pay structure. Its verified pricing includes a $39 first-month promotion, $178 per month all-in semaglutide, and $278 per month all-in tirzepatide. The regulatory distinction between compounded and FDA-approved medications remains an important consideration.
Both providers are classified as Top Tier in the GLP-1 Reviews methodology. Use the comparison according to your situation: PlushCare for primary-care integration, insurance-first access, and brand-name medication focus; Mochi Health for flat-rate self-pay pricing and specialist weight-management support.
This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any medication.
Corrected 8 October 2026. An earlier version of this article said Mochi Health provides a certificate of analysis (CoA), showing an image to that effect, and stated as fact that Mochi is LegitScript certified. That was our error, copied from our earlier Mochi review: its site does not offer a CoA, and we have not independently verified its LegitScript certification.
Corrected 9 October 2026. We removed a generated image from this article. Generated images on this site no longer show certifications, organisations, products, prices or figures unless the specific claim has been checked.
Corrected 13 October 2026. This article said Mochi Health claims LegitScript certification. Mochi’s own pages (read 7, 8 and 13 October 2026) make no such claim, so that has been removed. The claim came from our earlier Mochi review.
Corrected 14 October 2026: this article previously gave Better Business Bureau ratings for providers it compares, taken from our April 2026 research. We kept no record of where those ratings came from, so they have been removed.
Keep exploring our GLP-1 resources:
